Deal

Investinor invests in SantoSolve

Investinor has invested NOK 15 million in the Norwegian pharmaceutical company SantoSolve AS.


The company develops targeted pain therapeutics, based on a novel class of active ingredients. The company’s technology is covered by a broad range of patent applications, providing strong IPR protection. SantoSolve developes topical analgesic products based on non-radioactive strontium as the active substance.

SantoSolve was founded in 2002 and is located in Oslo.

Read more


FundInvestinor
Portfolio CompanySantoSolve
Date of Transaction2009-10-27
TransactionAcquisition
Seller
Buyer
Size of TransactionNOK 15.0m
Ind. FocusLife Science
GeographyNorway
StageVenture
 

More deals

(2011-07-13)